KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Liabilities: 2009-2024

Historic Total Liabilities for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $2.4 billion.

  • Ionis Pharmaceuticals' Total Liabilities fell 0.14% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 0.14%. This contributed to the annual value of $2.4 billion for FY2024, which is 7.22% down from last year.
  • As of FY2024, Ionis Pharmaceuticals' Total Liabilities stood at $2.4 billion, which was down 7.22% from $2.6 billion recorded in FY2023.
  • Ionis Pharmaceuticals' Total Liabilities' 5-year high stood at $2.6 billion during FY2023, with a 5-year trough of $1.6 billion in FY2020.
  • In the last 3 years, Ionis Pharmaceuticals' Total Liabilities had a median value of $2.4 billion in 2024 and averaged $2.3 billion.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Total Liabilities soared by 32.76% in 2023, and later declined by 7.22% in 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Total Liabilities (Yearly) stood at $1.6 billion in 2020, then rose by 11.75% to $1.8 billion in 2021, then rose by 6.58% to $2.0 billion in 2022, then skyrocketed by 32.76% to $2.6 billion in 2023, then decreased by 7.22% to $2.4 billion in 2024.